Edward B. Garon, MD, on Capmatinib in METex14-Mutated Advanced NSCLC: Expert Perspective

Posted: Wednesday, May 13, 2020

Edward B. Garon, MD, of the University of California, Los Angeles David Geffen School of Medicine, discusses implications of the GEOMETRY mono-1 trial, which suggest capmatinib is efficacious against brain metastases in patients with non–small cell lung cancer—a significant issue for this population—with a manageable toxicity profile.